110105-31-2

Basic information

• Product Name: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE
• Synonyms: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE;N-(Pyridin-2-yl)piperidine-4-carboxamide;N-2-pyridinyl-4-Piperidinecarboxamide
• CAS NO: 110105-31-2
• Molecular Formula: C11H15N3O
• Molecular Weight: 205.26
• Mol File: 110105-31-2.mol

Chemical Properties

• Boiling Point: 439.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.177±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.27±0.20(Predicted)
• CAS DataBase Reference: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE(110105-31-2)
• EPA Substance Registry System: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE(110105-31-2)

Safety Data

• Hazardous Substances Data: 110105-31-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE is used as a building block for the synthesis of various pharmaceuticals and compounds due to its unique heterocyclic structure and potential bioactivity.
Used in Antiviral Applications:
PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE is used as a potential antiviral agent, leveraging its chemical properties to combat viral infections, although further research is needed to fully understand its efficacy and mechanism of action.
Used in Antibacterial Applications:
PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE is used as a potential antibacterial agent, indicating its possible role in fighting bacterial infections, with ongoing studies to determine its effectiveness and mode of action.
Used in Anticancer Applications:
PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE is used as a potential anticancer agent, with studies exploring its ability to target and inhibit the growth of cancer cells, contributing to the development of novel therapeutic strategies against cancer.
Used in Research and Development:
PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-2-YLAMIDE is used as a research compound for the exploration of its chemical properties and potential applications in various scientific and medical fields, including the synthesis of new bioactive molecules.

Relevant articles and documents

VISUAL FUNCTION DISORDER IMPROVING AGENTS

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo?2,3-büpyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent

Preventives/remedies for kidney diseases

A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

Antitumor effect potentiators

When used concurrently with an antitumor agent, a compound having a Rho kinase inhibitory activity, such as (R)-(+)-N-(4-pyridyl)-4-(1-aminoethyl)benzamide, reinforces an antitumor effect of the antitumor agent and is useful as an antitumor effect potentiator. Particularly, a compound having a Rho kinase inhibitory activity used with an antitumor agent in combination can reduce the dose of the antitumor agent, which in turn affords provision of a sufficient effect and/or reduction of side effects.

Agent for prophylaxis and treatment of glaucoma

An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.

PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS

An agent for the prophylaxis and treatment of vascular constriction is provided, which contains a compound having a Rho kinase inhibitory activity. In particular, a compound having a Rho kinase inhibitory activity, for example, (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, suppresses regenerative intima proliferation after disorder of blood vessel and has various other actions. Therefore, it is useful as an agent for the prophylaxis and treatment of vascular constriction, specifically, an agent for the prophylaxis and treatment of vascular constriction induced by disorder of vascular wall, such as vascular restenosis that occurs after an operation of percutaneus transluminal coronary angioplasty, vascular restenosis that occurs after an operation of percutaneus transluminal angioplasty, vascular constriction that occurs after vascular reconstruction, such as DCA, operation of intravascular indwelling of stent and the like, and vascular constriction that occurs after organ transplantation.

PREVENTIVES/REMEDIES FOR LIVER DISEASES

The invention provides an agent for the prophylaxis and treatment of liver disease and an activation inhibitor of hepatic stellate cells, which contains a compound having a Rho kinase inhibitory activity. The compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, is useful for the prophylaxis and treatment of liver diseases, such as hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic cancer and the like, because it has various actions, such as a superior inhibitory action on the activation of hepatic stellate cell, suppressive action on hepatic fibrogenesis in liver tissues and the like.

PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS

An agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided.